Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07247279

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Conditions: Rare Diseases, Generalized Myasthenia Gravis (gMG)

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 450

Sponsor: AstraZeneca

Location: Research Site Kazan'

Summary

This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.

Eligibility Criteria

Inclusion Criteria: 1. Adults (≥18 years) diagnosed with generalized MG positive for acetylcholine receptor (AChR) antibodies. 2. Provision of signed and dated written informed consent. Exclusion Criteria: 1. Participants currently enrolled in clinical studies for treatment of gMG. 2. Ocular MG only.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07247279). StuddyBuddy aggregates publicly available trial information.